GRAIL Management to Address Morgan Stanley Healthcare Conference
Executives from Menlo Park-based cancer screening firm GRAIL are scheduled to outline their diagnostic strategy at the Morgan Stanley 24th Annual Global Healthcare Conference. The presentation, slated for September 14 at 11:30 a.m. ET in New York, will highlight the company's progress in early-stage oncology detection.
The biotech firm, which trades under the ticker GRAL, intends to provide insights into its current clinical initiatives and the application of its methylation-based platform. Investors and industry stakeholders can access a live broadcast of the session through the company’s investor relations portal. Following the event, the company plans to maintain an archived version of the webcast for a minimum of 30 days.
GRAIL currently focuses on utilizing next-generation sequencing and machine learning to identify multiple deadly cancer types before they reach advanced stages. Beyond initial screening, the company’s technology supports precision oncology efforts, including biomarker subtyping and the monitoring of treatment efficacy or recurrence. The firm maintains operations across Menlo Park, Washington, D.C., North Carolina, and the United Kingdom.
Comments (0)
No comments yet. Be the first!